TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. SPY
3. IONS
4. AAPL
5. ACN
6. AZN
7. ROIV
8. ORCL
9. HOOD
10. QCOM

Go back to TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer
ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 2,894,323       

ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 2,894,323       

ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 2,894,323